CA2658361C - Ophthalmic formulations for the treatment of inflammation - Google Patents

Ophthalmic formulations for the treatment of inflammation Download PDF

Info

Publication number
CA2658361C
CA2658361C CA2658361A CA2658361A CA2658361C CA 2658361 C CA2658361 C CA 2658361C CA 2658361 A CA2658361 A CA 2658361A CA 2658361 A CA2658361 A CA 2658361A CA 2658361 C CA2658361 C CA 2658361C
Authority
CA
Canada
Prior art keywords
compound
alkyl
compounds
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2658361A
Other languages
English (en)
French (fr)
Other versions
CA2658361A1 (en
Inventor
C. Eric Schwartz
Per Gjorstrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resolvyx Pharmaceuticals Inc
Original Assignee
Resolvyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolvyx Pharmaceuticals Inc filed Critical Resolvyx Pharmaceuticals Inc
Publication of CA2658361A1 publication Critical patent/CA2658361A1/en
Application granted granted Critical
Publication of CA2658361C publication Critical patent/CA2658361C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2658361A 2006-07-19 2007-07-19 Ophthalmic formulations for the treatment of inflammation Expired - Fee Related CA2658361C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83186606P 2006-07-19 2006-07-19
US60/831,866 2006-07-19
PCT/US2007/016338 WO2008011085A1 (en) 2006-07-19 2007-07-19 Compositions and methods for the treatment of mucositis

Publications (2)

Publication Number Publication Date
CA2658361A1 CA2658361A1 (en) 2008-01-24
CA2658361C true CA2658361C (en) 2013-04-23

Family

ID=38617335

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2658361A Expired - Fee Related CA2658361C (en) 2006-07-19 2007-07-19 Ophthalmic formulations for the treatment of inflammation

Country Status (14)

Country Link
US (1) US20100035989A1 (https=)
EP (1) EP2049099A1 (https=)
JP (1) JP2009545527A (https=)
KR (1) KR20090040323A (https=)
CN (1) CN101528218A (https=)
AU (1) AU2007275658B2 (https=)
BR (1) BRPI0714562A2 (https=)
CA (1) CA2658361C (https=)
IL (1) IL196465A0 (https=)
MX (1) MX2009000657A (https=)
RU (1) RU2009101324A (https=)
SG (1) SG173397A1 (https=)
WO (1) WO2008011085A1 (https=)
ZA (1) ZA200900388B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) * 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
JP2011519373A (ja) 2008-05-01 2011-07-07 コンプレクザ インコーポレイテッド ビニル置換脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2299997A4 (en) 2008-06-19 2012-01-11 Univ Utah Res Found USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
EP2393353A4 (en) * 2009-02-05 2013-12-25 Resolvyx Pharmaceuticals Inc COMPOSITIONS AND METHODS OF ORGAN CONSERVATION
WO2010095706A1 (ja) 2009-02-20 2010-08-26 国立大学法人東京大学 新規抗炎症性化合物
EP3045167A1 (en) 2009-07-31 2016-07-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Keto fatty acids as anti-inflammatory agents
EP2483233A4 (en) 2009-10-02 2013-08-14 Complexa Inc HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
WO2013116753A1 (en) * 2012-02-03 2013-08-08 University Of Pittsburgh-Of The Commonwelth System Of Higher Education Fatty acids as anti-inflammatory agents
CN103417471A (zh) * 2012-05-22 2013-12-04 吴升华 一种治疗湿疹等皮肤炎症的脂氧素乳膏
KR101621856B1 (ko) 2013-08-19 2016-05-17 한국생명공학연구원 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물
US20170000752A1 (en) * 2014-01-24 2017-01-05 Kyoto University Anti-inflammatory agent containing rare fatty acid
JP6321886B2 (ja) 2014-05-15 2018-05-09 エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 白血球減少症及び血小板減少症に対する治療方法
PT3865484T (pt) 2015-07-07 2024-01-30 H Lundbeck As Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas
WO2017059451A1 (en) 2015-10-02 2017-04-06 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
CA3100988A1 (en) 2018-05-25 2019-11-28 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
CA3110680A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576758A (en) * 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US6887901B1 (en) * 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US6353026B1 (en) * 1999-03-18 2002-03-05 Brigham And Women's Hospital Regulation of phospholipase D activity
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7700650B2 (en) * 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
WO2002070068A2 (en) * 2001-03-02 2002-09-12 The Brigham And Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
AU2002349297A1 (en) * 2001-12-03 2003-06-17 Kobenhavns Amt Statin-like compounds
CA2467580C (en) * 2001-12-18 2012-10-30 Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
WO2003053423A2 (en) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
AU2003260687A1 (en) * 2002-04-01 2003-10-20 University Of Southern California Trihydroxy polyunsaturated eicosanoids
JP2005529945A (ja) * 2002-06-17 2005-10-06 リソルヴィックス ファーマシューティカルズ オメガ−３ｐｕｆａ由来の脂質メディエーターの類似体及び使用方法
DE60330154D1 (de) * 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004110426A1 (en) * 2003-06-01 2004-12-23 Petasis Nicos A Modulation of airway inflammation in patients with cystic fibrosis and related diseases
US20050203184A1 (en) * 2003-09-10 2005-09-15 Petasis Nicos A. Benzo lipoxin analogues
BRPI0516803A (pt) * 2004-11-19 2008-09-23 Martek Biosciences Corp oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases

Also Published As

Publication number Publication date
KR20090040323A (ko) 2009-04-23
SG173397A1 (en) 2011-08-29
AU2007275658B2 (en) 2011-09-01
CA2658361A1 (en) 2008-01-24
JP2009545527A (ja) 2009-12-24
WO2008011085A1 (en) 2008-01-24
US20100035989A1 (en) 2010-02-11
EP2049099A1 (en) 2009-04-22
BRPI0714562A2 (pt) 2013-04-02
MX2009000657A (es) 2009-05-28
CN101528218A (zh) 2009-09-09
AU2007275658A1 (en) 2008-01-24
RU2009101324A (ru) 2010-07-27
ZA200900388B (en) 2010-03-31
IL196465A0 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
CA2658361C (en) Ophthalmic formulations for the treatment of inflammation
CA2699483A1 (en) Compositions and methods for modulating immune function
US5411988A (en) Compositions and methods for inhibiting inflammation and adhesion formation
WO2008070129A2 (en) Compositions and methods for the treatment of inflammatory disease
JP2001517213A (ja) Ｈｅｌｉｃｏｂａｃｔｅｒ種による感染症の予防および治療用経口製剤
JP2000515864A (ja) 骨のミネラル含有量を維持または増大させるための共役リノール酸
TWI324589B (en) Halogenated bioactive lipid compound
RU2468800C2 (ru) Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
JP5347195B2 (ja) 殺菌剤、静菌剤及び抗炎症に関する方法と組成
US10568866B1 (en) Composition and its use for increasing innate immune health
US20080161274A1 (en) Compounds and methods for inhibition of bone loss
EP3445372A1 (en) Use of thyroid beta-agonists
CN1248166A (zh) 抗癌组合物
US9388155B1 (en) Coumarin derivatives for cancer therapy
AU2016340017A1 (en) Compositions and methods for the treatment of diseases involving mucin
RU2235543C1 (ru) Способ повышения неспецифической резистентности организма
JP5928787B2 (ja) 皮膚線維化抑制剤
JP2005035951A (ja) 腫瘍転移抑制剤
US20080145409A1 (en) Composition for the treatment and prevention of peptic ulcer
WO2016165770A1 (en) 4-phenylbutyric acid derivatives
WO2008088314A2 (en) A composition for the treatment and prevention of peptic ulcer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180719